Despite these important functions in anti-tumor immune responses, clinical use of IFN-γ for cancer treatment in general and for antitumor activation of TAMs in particular has so far been hampered by significant dose-limiting toxicities and the complex pleiotropic effects of IFN-γ on a large number of different cell types (52). This evidence concerns the gene IFNG and cancer.